Generated by AI
Onconetix Inc. is a commercial-stage biotechnology company focused on solutions for men’s health and oncology. The company develops and commercializes proprietary therapeutics, diagnostics, and clinician-focused services, with an emphasis on prostate cancer and related urologic conditions. Its product portfolio includes Proclarix, a blood-based diagnostic test used in prostate cancer assessment, and Entadfi, an oral therapy for benign prostatic hyperplasia. Onconetix also works on expanding its oncology diagnostics and treatment offerings through research, development, and commercialization activities across key international markets, including the United States and Europe. Headquartered in Cincinnati, Ohio, Onconetix Inc. operates at the intersection of diagnostic testing and therapeutic care, serving healthcare providers and patients in specialized cancer and men’s health settings.
Website201 East Fifth Street
Cincinnati, OH, 45202
United States
The latest articles about ONCO.
Echo Tabletop Priced at $11,950 and Echo Full Body at $59,950; First Production Run of 250 Units Available for 2027 Delivery; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio , Oct. 27, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC (“Realbotix”), the target of Onconetix’s
CINCINNATI, Ohio, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”), today announced that its Board of Directors has approved a one-for-ten (1-for-10) reverse stock split of the Company’s outstanding common stock. The reverse split is expected to become effective at 12:01 a.m. Eastern Time on November 6, 2026. The Company’s common stock has been assigned a new CUSIP number, 68237Q500, in connection with the reverse stock split. Following the reverse split, every te
Summary of Nov 9's posts. Generated by AI.
Summary of Oct 29's posts. Generated by AI.
Summary of Oct 29's posts. Generated by AI.
Investors talking about ONCO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.